Solarea Bio Aims to Transform Dietary Management of Age-Related Health Conditions with New Class of Medical Foods

The company's consumer health brand, Journa^TM, demonstrates novel applications of probiotic microbes isolated from fruits and vegetables to improve the aging experience.

BOSTON, Feb. 19, 2025 /PRNewswire/ -- Solarea Bio enters 2025 following an impactful year of pioneering natural solutions for some of the most prevalent age-related health conditions, including postmenopausal bone loss and chronic autoimmune diseases. The company recently introduced its consumer health brand, Journa^TM, powered by the pioneering science of Solarea Bio, to improve the aging experience with natural, clinically validated solutions.

Journa's proprietary platform, Microscape Technology^TM, an artificial intelligence-driven product engine, enables faster commercialization of products in the pipeline. Expert scientists can quickly isolate microbes naturally found in fruits, vegetables, and fermented foods, sequencing the full genome of each isolate for a comprehensive microbial library. This library includes over 5,000 microbial isolates, more than 16 million genes, and over seven million biosynthetic clusters. Candidates are then developed into Defined Microbial Assemblages (DMAs) and tested in randomized, placebo-controlled human clinical trials. In 2024, its R&D team enhanced the platform's ability to predict the function of individual food-derived probiotic strains and to predict functional synergies between strains to accelerate DMA design and development.

Journa has since announced early access to its scientifically formulated daily synbiotic medical food, Bondia™ (SBD111), designed to aid in the dietary management of bone loss associated with osteopenia, menopause, weight, and age. The product specifically targets bone loss, which disproportionately affects women in cases of osteopenia and osteoporosis. Bondia will launch in the fall of 2025 following the publication of data from a large, randomized, placebo-controlled clinical food trial in 286 postmenopausal women. Journa is building momentum by working directly with practitioners and offering their patients early access and unique promotions to purchase Bondia.

"The age-related inflammatory condition osteopenia is a great unmet need, with consumers lacking a safe, effective solution to manage postmenopausal bone loss," noted Gerardo V. Toledo, co-founder and CEO of Solarea Bio and Journa. "Medical food presents a new opportunity to support bone health and slow bone loss associated with osteopenia, menopause, weight, and aging."

Additional products in Journa's pipeline target rheumatoid arthritis, with a human clinical trial underway.

"Journa will transform the women's health marketplace for osteopenia by bringing Bondia to market this fall. Healthcare practitioners are encouraged to expand their toolbox and recommend Bondia to their patients, innovating the modern health journey," explained Eric Schott, co-founder and COO of Solarea Bio and Journa.

Fueling Solarea Bio's and Journa's momentum has been the addition of three new team members: Ilissa Larimore, Chief Commercial Officer, Lisa McDonald, Vice President of Commercial Development, and the appointment of advisory board member Gina Woods, MD, Professor of Medicine at UC San Diego, Co-Chief, Division of Endocrinology and Director, Osteoporosis Clinic.

To learn more about Journa or synbiotic Bondia, please visit this website. If you're a practitioner interested in knowing more about Bondia, please send inquires to [email protected].

About Solarea Bio
Solarea Bio is a biotechnology company based in Waltham, MA, that's committed to advancing the future of aging and measurably improving collective health outcomes. The company has built a best-in-class strain catalog of bacterial and fungal diversity representing fresh fruits and vegetables, a database of their genomes, and a computational platform to mine them to develop medical foods. Solarea Bio incorporates the highest level of scientific rigor into every aspect of its process, validating products in robust randomized, placebo-controlled clinical food trials to create novel solutions for managing inflammatory diseases. To learn more, please visit: https://www.solareabio.com/.

Media Contact
SVM PR
Kay Blazar
[email protected] 

SOURCE Solarea Bio